Facilitating Payment Reform Pathways for Antimicrobial Drugs through FDA and CMS Collaboration

As you know, the rise in antimicrobial resistant infections is a major public health threat. Few treatment options are available and the pipeline of drug candidates is extremely limited. To help address this issue, Duke-Margolis has been focused on policy initiatives that could encourage development of antimicrobial products through post-market incentives.

Participants include Kevin Outterson, Executive Director of CARB-X